Vaccinogen Inc. entered into an agreement with Dublin City University, through one of its subsidiaries, to provide an exclusive two-year option to evaluate and acquire a high-throughput, multiplex, analysis platform, DiCAST.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
